Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Wang, Yumei ^a   Landheer, Sjoerd ^b   van Gilst, Wiek H ^b   van Amerongen, Aart ^c   Hammes, Hans Peter ^a   Henning, Robert H ^b   Deelman, Leo E ^b   Buikema, Hendrik ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CELL PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRINKING WATER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCAGON LIKE PEPTIDE 1; INDOMETACIN; INTERLEUKIN 13; INTERLEUKIN 1BETA; MESSENGER RNA; NWT 03; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROTEIN HYDROLYSATE; PROTEIN P22 PHOX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VILDAGLIPTIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM DEPENDENT RELAXATION; ENZYME INHIBITION; FUNCTIONAL FOOD; GENE EXPRESSION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENOVASCULAR DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TREATMENT DURATION; VASCULAR RING; WESTERN BLOTTING; ZUCKER DIABETIC FATTY RAT;

ACETYLCHOLINE; ADAMANTANE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; BLOOD PRESSURE; BLOTTING, WESTERN; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; E-SELECTIN; EGG PROTEINS; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; KIDNEY; NITRILES; PEPTIDYL-DIPEPTIDASE A; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN HYDROLYSATES; PYRROLIDINES; RATS; RATS, INBRED SHR; RATS, ZUCKER; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASODILATION; VASODILATOR AGENTS;

EID: 84867351013     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046781     Document Type: Article

References (41)

1. Hartmann R, Meisel H, (2007) Food-derived peptides with biological activity: from research to food applications. Curr Opin Biotechnol 18: 163-169.
2. Vermeirrsen V, van der Bent A, Van Camp J, van Amerongen A, Verstraete W, (2004) A quantitative in silico analysis calculates the angiotensin I converting enzyme (ACE) inhibitory activity in pea and whey protein digests. Biochimie 86: 231-239.
3. Vercruysse L, Smagghe G, van der Bent A, van Amerongen A, Ongenaert M, et al. (2009) Critical evaluation of the use of bioinformatics as a theoretical tool to find high-potential sources of ACE inhibitory peptides. Peptides 30: 575-582.
4. Basile J, Toth PP, (2009) Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J 102 (Suppl 10):: S1-12.
5. Enseleit F, Hürlimann D, Lüscher TF, (2001) Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 37 (Suppl 1):: S21-30.
6. Drucker DJ, (2006) The biology of incretin hormones. Cell Metab 3: 153-165.
7. Combettesa MM, (2006) GLP-1 and type 2 diabetes: physiology and new clinical advances. Curr Opin Pharmacol 6: 598-605.
8. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, et al. (2005) Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315: 688-695.
9. Csermely P, Agoston V, Pongor S, (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26: 178-182.
10. Smit-van Oosten A, Navis G, Stegeman CA, Joles JA, Klok PA, et al. (2005) Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J Pathol 194: 122-129.
11. Rook M, Lely AT, Kramer AB, van Goor H, Navis G, (2005) Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant 20: 59-64.
12. Sandovici M, Henning RH, van Goor H, Helfrich W, de Zeeuw D, et al. (2008) Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Kidney Int 73: 1364-1373.
13. Sandovici M, Henning RH, Hut RA, Strijkstra AM, Epema AH, et al. (2004) Differential regulation of glomerular and interstitial endothelial nitric oxide synthase expression in the kidney of hibernating ground squirl. Nitric Oxide 11: 194-200.
14. Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, et al. (2000) Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 130: 1999-2007.
15. Gschwend S, Pinto-Sietsma SJ, Buikema H, Pinto YM, van Gilst WH, et al. (2002) Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney Int 62: 181-191.
16. Rizvi AA, (2009) Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci 338: 310-318.
17. Mizuno M, Sada T, Kato M, Koike H, (2002) Renoprotective effects of blockade angiotensin II AT1 receptors in an animal of type 2 diabetes. Hypertens Res 25: 271-278.
18. DeFronzo RA, Ferranannini E, Simonson DC, (1989) Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired glucose uptake. Metabolism 8: 387-395.
19. Unger RH, Orci L, (2001) Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 15: 312-321.
20. Etgen GJ, Oldham BA, (2000) Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 49: 684-688.
21. Schäfer S, Linz W, Bube A, Gerl M, Huber J, et al. (2003) Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res 60: 447-454.
22. Chander PN, Gealekman O, Brodsky SV, Elitok S, Tojo A, et al. (2004) Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 15: 2391-2403.
23. Suzaki Y, Ozawa Y, Kobori H, (2006) Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci 3: 40-46.
24. Harris RC, (2008) An update on cyclooxygenase-2 expression and metabolites in the kidney. Curr Opin Nephrol Hypertens 17: 64-69.
25. Hao CM, Breyer MD, (2007) Roles of lipid mediators in kidney injury. Semin Nephrol 27: 338-351.
26. Hao CM, Breyer MD, (2008) Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70: 357-377.
27. Komers R, Zdychová J, Cahová M, Kazdová L, Lindsley JN, et al. (2005) Renal cyclooxygenase-2 in obese Zucker (fatty) rats. Kidney Int 67: 2151-2158.
28. Retailleau K, Belin de Chantemèle EJ, Chanoine S, Guihot AL, Vessières E, et al. (2010) Reactive oxygen species and cyclooxygenase 2-derived thromboxane A2 reduce angiotensin II type 2 receptor vasorelaxation in diabetic rat resistance arteries. Hypertension 55: 339-344.
29. Palalau AI, Tahrani AA, Piya MK, Barnett AH, (2009) DPP-4 inhibitors in clinical practice. Postgrad Med 121: 70-100.
30. Moore KB, Saudek CD, (2008) Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. Am J Ther 15: 484-491.
31. Sudre B, Broqua P, White RB, Asworth D, Evans DM, et al. (2002) Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51: 1461-1469.
32. Thomas L, Tadayyon M, Mark M, (2009) Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 328: 556-563.
33. Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, et al. (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310: 28-31.
34. Aytac U, Dang NH, (2004) CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 4: 11-18.
35. Klahr S, Morrissey J, (1998) Angiotensin II and gene expression in the kidney. Am J Kidney Dis 31: 171-176.
36. Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, et al. (2003) Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 52: 2570-2577.
37. Jaimes EA, Tian RX, Pearse D, Raij L, (2005) Up-regulation of glomerular COX-2 by angiotensin II: role of reactive oxygen species. Kidney Int 68: 2143-2153.
38. Xu ZG, Lanting L, Vaziri ND, Li Z, Sepassi L, et al. (2005) Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney. Reversal by angiotensin II type 1 receptor blockade. Circulation 111: 1962-1969.
39. Da Ros R, Assaloni R, Ceriello A, (2004) Antioxidant therapy in diabetic complications: what is new? Curr Vasc Pharmacol 2: 335-341.
40. Oltman CL, Kleinschmidt TL, Davidson EP, Coppey LJ, Lund DD, et al. (2008) Treatment of cardiovascular dusfunction associated with the metabolic syndrome and type 2 diabetes. Vasc Pharmacol 48: 47-53.
41. American Diabetes Association (2008) Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, et al. (2008) Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 31 (Suppl 1):: S61-78.